Gene Function & Regulation
Gene function and regulation are central to understanding biological processes and disease mechanisms. From the regulation of gene expression by non-coding RNAs like miRNAs to gene expression analysis and CRISPR-based gene editing, the ability to manipulate and measure gene function is crucial for advancing research in genetics, disease biology, and drug discovery.
Signosis offers a broad array of tools and technologies that empower researchers to explore gene function and regulatory mechanisms at multiple levels. Whether you're studying gene expression, miRNA regulation, or employing CRISPR to modify genes, our products are designed to give you precision, efficiency, and reliability.
Explore our Gene Function & Regulation solutions by browsing the sections below:
CRISPR Products – Cutting-edge CRISPR technology for gene editing, regulation, and functional studies.
miRNA Research – Tools for studying miRNA expression, regulation, and their role in diseases like cancer.
Gene Expression Analysis – Systems for monitoring gene expression, including TF regulation and single-cell PCR.
CRISPR Products
The CRISPR-Cas9 genome editing system has revolutionized genetic research by enabling precise, targeted alterations to the genome. Whether you’re studying gene function, validating therapeutic targets, or exploring gene regulation pathways, CRISPR provides a powerful and flexible platform for making systematic genetic modifications.
Signosis provides a comprehensive suite of CRISPR tools designed to support diverse research needs in gene function and regulation. Our CRISPR products are optimized for high efficiency, reliable gene editing, and customization, making them ideal for applications in functional genomics, pathway analysis, and therapeutic research.
Applications
Prostate Cancer and Castration-Resistant Prostate Cancer (CRPC)
Signosis' AR luciferase reporter cell line is a powerful and versatile model for studying AR signaling in prostate cancer, including both hormone-sensitive and castration-resistant stages (CRPC). Since AR remains a central driver of tumor progression even after androgen deprivation therapy (ADT), our AR luciferase reporter cell lines are ideal for understanding the molecular mechanisms of disease progress and identifying effective treatment strategies for prostate cancer.
This model enables quantifiable measurement of AR transcriptional activity in response to pharmacological or genetic modulation. It supports a wide range of applications, including but not limited to:
-
Evaluating the efficacy of AR-targeted therapies such as enzalutamide, bicalutamide, and flutamide
-
Studying mechanisms of drug resistance including AR mutations or splice variant expression such as AR-V7
-
Screening novel small molecules or biologics that activate or inhibit AR function
-
Exploring cross-talk with key oncogenic pathways, including PI3K/AKT/mTOR, Wnt/β-catenin, and FOXA1
Common inducers and inhibitors that can be used with this model:
-
Dihydrotestosterone (DHT) or R1881 to activate AR signaling
-
Enzalutamide or flutamide as AR antagonists to inhibit AR function
-
AKT inhibitors (such as MK-2206) to explore compensatory survival pathways and synergy with AR inhibition
Signosis offers AR luciferase reporter cell line for high-throughput drug screening, combination therapy testing, and mechanistic research into AR-driven oncogenesis.